ReviewThe Egyptian journal of neurology, psychiatry and neurosurgery2022
The relationship between myasthenia gravis and COVID-19: a systematic review.
Review in The Egyptian journal of neurology, psychiatry and neurosurgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.Journal of neuromuscular diseases · 2025Trial
- New-Onset Myasthenia Gravis Associated with SARS-CoV-2 Infection: A Systematic Review.Life (Basel, Switzerland) · 2026Review
- Trends in hospitalisation, myasthenic crisis and intensive care use in myasthenia gravis: a nationwide population-based study in Spain (2016-2022).Neurological research and practice · 2026Article
- Development of Multiple Autoimmune and Endocrine Disorders Following COVID-19 Vaccination: A Case Report.Cureus · 2025Article
- Anxiety in Myasthenia Gravis Patients Throughout the COVID-19 Pandemic-Prevalence, Risk Factors, and Association With Vaccination Status.Brain and behavior · 2025Article
- Rare Diseases, Spotlighting Amyotrophic Lateral Sclerosis, Huntington's Disease, and Myasthenia Gravis: Insights from Landscape Analysis of Current Research.Biochemistry · 2025Review
- The impacts of the COVID-19 pandemic on Australia's myasthenia gravis patients: A self-reported survey study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Observational
- Muscle weakness post-COVID: a practical guide for primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2024Article
- Authors' response to the Letter to the Editor.Skeletal radiology · 2024Article
- Review
- Article
- COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Review
- Systemic Inflammatory Response Index, a Potential Inflammatory Biomarker in Disease Severity of Myasthenia Gravis: A Pilot Retrospective Study.Journal of inflammation research · 2024Article
- Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study.Frontiers in public health · 2024Article
- The Incidence of Myasthenia Gravis in the Province of Ferrara, Italy, in the Period of 2008-2022: An Update on a 40-Year Observation and the Influence of the COVID-19 Pandemic.Journal of clinical medicine · 2023Article
- Peripheral immune landscape for hypercytokinemia in myasthenic crisis utilizing single-cell transcriptomics.Journal of translational medicine · 2023Article
- Autoimmune myasthenia gravis and COVID-19. A case report-based review.The Journal of international medical research · 2023Review
- Review of Neurological Manifestations of SARS-CoV-2.Cureus · 2023Review
- Clinical Characteristics of Myasthenia Gravis Patients with COVID-19 in Guangxi, China: A Case-Control Study.Journal of inflammation research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Viral infection such as coronavirus disease 2019 (COVID-19) can exacerbate and aggravate neurological disorders due to autoimmune etiology like myasthenia gravis (MG). Experimental therapies used in COVID-19 are also factors that can cause the worsening of MG symptoms. This review aimed to assess and conclude the research-based study systematically to analyze the relationship of MG and COVID-19. Method: This study was conducted in accordance to Cochrane handbook for systematic reviews and the guideline of preferred reporting items for systematic review and meta-analysis (PRISMA) and synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. Inclusion criteria in this review were primary studies of every design, articles published in English around January 2000-October 2021, and the study used human as subject. A systematic literature finding was applied in 15 electronic scientific resources. The authors evaluated the study quality and risk of bias of each retrieved article. Results: The authors found the study through electronic scientific resources that met inclusion and exclusion criteria. The authors evaluated 362 articles identified in literature searching, 22 articles met the criteria for this review and then underwent the evaluation of study quality and risk of bias. Conclusion: COVID-19 infection can increase the risk of new-onset MG, myasthenic crisis, respiratory failure, and mortality rate due to cytokine storm in MG patients. The management of COVID-19 patients with MG is tailored to each person and based on national guidelines and local expert recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.